RMEBX
Price
$64.44
Change
+$0.03 (+0.05%)
Updated
Jul 31 closing price
Net Assets
118.05B
WLCVX
Price
$24.99
Change
+$0.07 (+0.28%)
Updated
Jul 31 closing price
Net Assets
184.72M
Interact to see
Advertisement

RMEBX vs WLCVX

RMEBX vs WLCVX Comparison Chart in %
View a ticker or compare two or three
VS
RMEBX vs. WLCVX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RMEBX is a Buy and WLCVX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RMEBX has more cash in the bank: 118B vs. WLCVX (185M). WLCVX pays higher dividends than RMEBX: WLCVX (1.11) vs RMEBX (0.99). RMEBX was incepted earlier than WLCVX: RMEBX (12 years) vs WLCVX (30 years). RMEBX (1.07) and WLCVX (1.03) have similar cost to investors . WLCVX is a more actively managed with annual turnover of: 51.00 vs. RMEBX (30.00). RMEBX has a lower initial minimum investment than WLCVX: RMEBX (250) vs WLCVX (250000). WLCVX annual gain was more profitable for investors over the last year : 14.01 vs. RMEBX (8.96). RMEBX return over 5 years is better than : 36.13 vs. WLCVX (13.12).
RMEBXWLCVXRMEBX / WLCVX
Total Expense Ratio1.071.00107%
Annual Report Gross Expense Ratio1.071.03104%
Fund Existence12 years30 years-
Gain YTD9.41614.63364%
Front LoadN/AN/A-
Min. Initial Investment2502500000%
Min. Initial Investment IRAN/AN/A-
Net Assets118B185M63,784%
Annual Yield % from dividends0.991.1189%
Returns for 1 year8.9614.0164%
Returns for 3 years32.6331.06105%
Returns for 5 years36.1313.12275%
Returns for 10 years90.6447.48191%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IEOTX15.100.17
+1.14%
Voya Large Cap Growth Port S2
JRAAX88.86N/A
N/A
Janus Henderson Research A
VLLIX45.39-0.03
-0.07%
Value Line Larger Companies Focus Instl
BHCFX21.68-0.10
-0.46%
Baron Health Care Retail
FBDIX193.96-3.99
-2.02%
Franklin Biotechnology Discovery A